Drug Profile
FPF 1070
Alternative Names: CerebrolysinLatest Information Update: 25 Dec 2023
Price :
$50
*
At a glance
- Originator Ebewe Neuro Pharma
- Developer EVER Neuro Pharma
- Class Nootropics; Peptides; Tissue extracts
- Mechanism of Action Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alzheimer's disease; Stroke
- Phase II CADASIL
- Discontinued Brain injuries
Most Recent Events
- 29 Nov 2023 Phase-II clinical trials in CADASIL in Czech Republic (unspecified route) (NCT05755997) (EudraC2022-002394-29)
- 28 Jul 2022 Ever Neuro Pharma terminates a phase II IMPULSE trial in Stroke in Austria due to strategic and pandemic reasons (NCT04124367)
- 25 Jun 2021 Ever Neuro Pharma initiates a phase II IMPULSE trial for Stroke in Austria (NCT04124367)